Clinical Trial Update: Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain [Phase 4]

View source ↗

Summary

Phase 4 safety and pharmacokinetic study of ALO-02 in children aged 7-17 with moderate to severe pain was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Moderate-severe Pain
• Pain Unspecified

Drugs mentioned

• ALO-02 (oxycodone/naloxone)

Snippet

Sponsor: Pfizer | Conditions: Moderate-severe Pain | Phase 4 | Status: TERMINATED | Results posted: 2018-09-25